The first 60 days: Multiple myeloma
Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC. Below, week by week, is what OnCo's record of Multiple myeloma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Dara-VRd ± ASCT → lenalidomide maintenance.
- Newly diagnosed, transplant-eligibleNCCN category Category 1 (Dara-VRd), ESMO-MCBS A, NCCN 2026 / EHA-ESMO 2021 update
Dara-VRd (or Isa-VRd) induction × 4-6 → stem-cell collection → high-dose melphalan + autologous transplant → Dara-VRd consolidation → lenalidomide (± daratumumab) maintenance; MRD-guided de-escalation emerging (PERSEUS design). Tandem transplant or extended therapy for high risk.
- Newly diagnosed, transplant-ineligibleNCCN category Category 1, NCCN 2026
Dara-VRd (CEPHEUS) or Isa-VRd (IMROZ) with bortezomib de-escalation after induction; Dara-Rd (MAIA) for frailer patients; continuous therapy with dose adjustment for frailty.
- Serum and urine protein studies, free light chains, bone marrow biopsy with FISH for high-risk changes, whole-body low-dose CT or PET-CT.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Relapsed.
- RadiologistNamed in the standard of care for: Newly diagnosed.
- Medical oncologistNamed in the standard of care for: Relapsed, High-risk smouldering myeloma, Newly diagnosed, transplant-eligible, Newly diagnosed, transplant-ineligible and 4 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Supportive care.
- Transplant and cell therapy teamNamed in the standard of care for: Relapsed, Newly diagnosed, transplant-eligible, First relapse (1-3 prior lines), Triple-class refractory (≥3-4 prior lines).
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.High-risk smouldering myelomaNCCN category Category 2A (daratumumab or lenalidomide for high-risk SMM), NCCN 2026
Consider daratumumab monotherapy (AQUILA) or lenalidomide (E3A06), or trial enrolment; shared decision given indolent course in many.
Observation with periodic labs; no treatment outside trials.
CAR-T or bispecific; belantamab combinations; sequencing by prior exposure.
- 4.First relapse (1-3 prior lines)NCCN category Category 1 (cilta-cel ≥1 line; tec-dara ≥1 line), NCCN 2026
Cilta-cel if lenalidomide-refractory (CARTITUDE-4); teclistamab + daratumumab (MajesTEC-3, 2026); ide-cel after ≥2 lines; belantamab-Vd or -Pd (DREAMM-7/8); CD38-based triplets (Dara-Kd, Isa-Kd, Dara-Pd) by prior exposure; carfilzomib or pomalidomide combinations.
BCMA CAR-T if not yet given; bispecifics (teclistamab, elranatamab, linvoseltamab; talquetamab after BCMA exposure); belantamab; selinexor-based; CELMoDs in trials; anito-cel (PDUFA Dec 2026).
Lenalidomide until progression (CALGB 100104, Myeloma XI); daratumumab added for high-risk or per PERSEUS; MRD-guided discontinuation in trials (DRAMMATIC, MASTER); iberdomide maintenance (EXCALIBER) pending.
Bisphosphonate or denosumab for bone disease; IVIG, antiviral, PJP prophylaxis and vaccination during T-cell redirection; thromboprophylaxis with IMiDs; renal protection; radiotherapy for painful lesions or cord compression.
- Transplant now or keep the cells for later?
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Cytogenetics, 1q gain), R-ISS, MRD, BCMA/GPRC5D expression, Serum and urine M-protein, free light chains), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Standard-risk vs high-risk cytogenetics, Transplant-eligible vs transplant-ineligible, Extramedullary disease.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
- For my situation (newly diagnosed), which of the standard options do you recommend and why?Guideline options include: Dara-VRd ± ASCT → lenalidomide maintenance.
Relapsed
- For my situation (relapsed), which of the standard options do you recommend and why?Guideline options include: CAR-T or bispecific; belantamab combinations; sequencing by prior exposure.
- Am I a candidate for Ciltacabtagene autoleucel, Teclistamab, Belantamab mafodotin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
MGUS / low-risk smouldering
- For my situation (mgus / low-risk smouldering), which of the standard options do you recommend and why?Guideline options include: Observation with periodic labs; no treatment outside trials.
- How do the results of iStopMM apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
High-risk smouldering myeloma
- For my situation (high-risk smouldering myeloma), which of the standard options do you recommend and why?Guideline options include: Consider daratumumab monotherapy (AQUILA) or lenalidomide (E3A06), or trial enrolment; shared decision given indolent course in many.
- Am I a candidate for Daratumumab, Lenalidomide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Newly diagnosed, transplant-eligible
- For my situation (newly diagnosed, transplant-eligible), which of the standard options do you recommend and why?Guideline options include: Dara-VRd (or Isa-VRd) induction × 4-6 → stem-cell collection → high-dose melphalan + autologous transplant → Dara-VRd consolidation → lenalidomide (± daratumumab) maintenance; MRD-guided de-escalation emerging (PERSEUS design). Tandem transplant or extended therapy for high risk.
- Am I a candidate for Daratumumab, Bortezomib, Lenalidomide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PERSEUS apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Newly diagnosed, transplant-ineligible
- For my situation (newly diagnosed, transplant-ineligible), which of the standard options do you recommend and why?Guideline options include: Dara-VRd (CEPHEUS) or Isa-VRd (IMROZ) with bortezomib de-escalation after induction; Dara-Rd (MAIA) for frailer patients; continuous therapy with dose adjustment for frailty.
- Am I a candidate for Daratumumab, Isatuximab, Lenalidomide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CEPHEUS and IMROZ apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Maintenance
- For my situation (maintenance), which of the standard options do you recommend and why?Guideline options include: Lenalidomide until progression (CALGB 100104, Myeloma XI); daratumumab added for high-risk or per PERSEUS; MRD-guided discontinuation in trials (DRAMMATIC, MASTER); iberdomide maintenance (EXCALIBER) pending.
- Am I a candidate for Lenalidomide, Daratumumab, Iberdomide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
First relapse (1-3 prior lines)
- For my situation (first relapse (1-3 prior lines)), which of the standard options do you recommend and why?Guideline options include: Cilta-cel if lenalidomide-refractory (CARTITUDE-4); teclistamab + daratumumab (MajesTEC-3, 2026); ide-cel after ≥2 lines; belantamab-Vd or -Pd (DREAMM-7/8); CD38-based triplets (Dara-Kd, Isa-Kd, Dara-Pd) by prior exposure; carfilzomib or pomalidomide combinations.
- Am I a candidate for Ciltacabtagene autoleucel, Teclistamab, Idecabtagene vicleucel or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CARTITUDE-4 and MajesTEC-3 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Triple-class refractory (≥3-4 prior lines)
- For my situation (triple-class refractory (≥3-4 prior lines)), which of the standard options do you recommend and why?Guideline options include: BCMA CAR-T if not yet given; bispecifics (teclistamab, elranatamab, linvoseltamab; talquetamab after BCMA exposure); belantamab; selinexor-based; CELMoDs in trials; anito-cel (PDUFA Dec 2026).
- Am I a candidate for Teclistamab, Elranatamab, Linvoseltamab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Supportive care
- For my situation (supportive care), which of the standard options do you recommend and why?Guideline options include: Bisphosphonate or denosumab for bone disease; IVIG, antiviral, PJP prophylaxis and vaccination during T-cell redirection; thromboprophylaxis with IMiDs; renal protection; radiotherapy for painful lesions or cord compression.
Any stage
- Are there clinical trials I could join, for example of Teclistamab, Ciltacabtagene autoleucel, Cevostamab, JNJ-79635322?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “High-risk cytogenetics”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Infections with T-cell redirecting therapy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsPhase 3 · recruiting · NCT06508983A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple MyelomaPhase 3 · recruiting · NCT07579234Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Phase 3 · recruiting · NCT06464991A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma
- A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to PlPhase 3 · active · NCT03246529A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaPhase 3 · active · NCT06413498A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Multiple myeloma: the full pageMultiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment journey: Newly diagnosed, transplant-eligibleFour to six months of a four-drug combination, a stem cell transplant with a hospital stay of a few weeks, two more cycles, then maintenance tablets that continue for years while the disease is monitored down to a few cells in a million.
- Guidelines comparedNCCN, ESMO and NICE side by side for this cancer.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶): MRD negativity means no detectable myeloma cell among 100,000 or a million marrow cells.
- VRd and Dara-VRd (myeloma induction regimens): The alphabet soup of myeloma treatment: V (bortezomib, Velcade), R (lenalidomide, Revlimid), d (dexamethasone), Dara (daratumumab), Isa (isatuximab), K (carfilzomib).
- Smouldering myeloma / MGUS: Early plasma-cell conditions with no organ damage; most never progress, but high-risk smouldering disease is now sometimes treated.
- Proteasome inhibitor (bortezomib, carfilzomib, ixazomib): Drugs that block the cell's protein-recycling machine.
- R-ISS / R2-ISS staging: R-ISS is the myeloma staging system, combining blood markers with high-risk chromosome changes to predict outcome.
- High-risk cytogenetics (myeloma): Chromosome changes such as del(17p), t(4;14), t(14;16) and extra copies of 1q that mark myeloma likely to relapse early.
- Immunomodulatory drugs (IMiDs) and CELMoDs: Thalidomide and its descendants lenalidomide and pomalidomide, which hijack a cellular waste-disposal tag (cereblon) to destroy two proteins myeloma cells depend on, while also revving up T and NK cells.
- ICANS (neurotoxicity): ICANS is confusion, speech difficulty, and rarely seizures after CAR-T or bispecific therapy.
- Cancer health disparities and equity: Systematic differences in who gets cancer, how early it is found and who survives, driven by race, income, geography, insurance and structural racism rather than biology alone.
- Fixed-duration vs continuous therapy: Whether a drug is taken for a set period (say 12 months) and then stopped even though it is still working, or continued indefinitely until it fails.
Every term links to the glossary.